Promega

Promega Corporation is an international biotechnology company that serves the life science research industry by providing innovative solutions, technical support, and a wide range of products for applications such as gene, protein, and cell analysis. Founded in 1978, the company has continued to develop and evolve technologies and instrumentation in collaboration with scientists and researchers worldwide.

Promega's portfolio includes tools for fundamental research, drug development, forensic science, clinical and molecular diagnostics, and applied testing. In 2021, the company received FDA clearance for the OncoMate MSI Dx Analysis System, which determines microsatellite instability status in colorectal tumors, aiding in the diagnosis of Lynch syndrome.

The company's emphasis on research and development is evident in its state-of-the-art facilities. The 280,000-square-foot Kornberg Center in Madison, Wisconsin, features laboratories with access to natural light, dedicated frontier spaces for exploring new technologies, and collaborative spaces to foster innovation. Similarly, Promega's German headquarters in Walldorf, completed in January 2024, integrates sustainable design elements like a photovoltaic roof, rainwater collection, and biophilic spaces to create an inviting work environment for employees.

Promega promotes a culture of well-being, emotional intelligence, and personal development among its workforce through various initiatives, such as guided meditations, training programs, and opportunities for creative thinking. The company's operations prioritize sustainability, with goals to reduce carbon emissions and increase renewable energy usage. As of 2022, over 20% of Promega's global electricity consumption comes from renewable sources, including solar arrays at its facilities.

Key customers and partnerships

In April 2024, Promega partnered with INOVIQ to generate commercial exosome isolation and nucleic acid extraction solutions. The partnership was aimed towards commercializing INOVIQ’s EXO-NET, a tool for capturing exosomes, with the help of Promega’s resources in nucleic acid purification.

In March 2022, Promega Corporation announced a strategic collaboration with FUJIFILM Cellular Dynamics to advance novel assay development for drug discovery. The agreement grants FUJIFILM Cellular Dynamics access to Promega's bioluminescent reporter technologies, enabling researchers to create new biosensor assays in induced pluripotent stem cell-derived cells, driving drug discovery assays toward greater human relevance.